Research Topics
| David J AdelsteinSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical trial design in head and neck cancer: what has the oncologist learned?David J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Lancet Oncol 13:e318-23. 2012....- Biology and management of salivary gland cancersDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Semin Radiat Oncol 22:245-53. 2012..These efforts have suggested the potential for molecularly targeted therapies, and clinical trials exploring this approach are currently underway... - Transoral resection of pharyngeal cancer: Summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, VirginiaDavid J Adelstein
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Head Neck 34:1681-703. 2012..The proceedings of this meeting are summarized. © 2012 Wiley Periodicals, Inc. Head Neck, 2012... - A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junctionDavid J Adelstein
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Invest New Drugs 30:1684-9. 2012..We report results from a phase II trial in this population using gefitinib, an oral epidermal growth factor receptor inhibitor... - What is new in the management of salivary gland cancers?David J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Curr Opin Oncol 23:249-53. 2011..Historically they have been treated with surgery and radiation therapy. It is only recently that there has been any growth in our understanding of these diseases and their management, and this progress will be reviewed... 
Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directionsDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Int J Radiat Oncol Biol Phys 69:S37-9. 2007- Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institutionDavid J Adelstein
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 24:1064-71. 2006..A retrospective review with long-term follow-up is reported from the Cleveland Clinic Foundation studying radiation and concurrent multiagent chemotherapy in patients with locoregionally advanced squamous cell head and neck cancer... - Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?David J Adelstein
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 24:2624-8. 2006..This treatment approach remains investigational however, and these phase III studies are critical. The current randomized trials are reviewed and discussed... - A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneityDavid J Adelstein
The Taussig Cancer Center and the Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
Am J Clin Oncol 30:172-80. 2007..A split course of pre- and postoperative hyperfractionated radiation therapy and concurrent chemotherapy was used in an effort to limit perioperative mortality... - Current and emerging standards of concomitant chemoradiotherapyDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Semin Oncol 35:211-20. 2008.... - Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junctionDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
J Thorac Oncol 4:1264-9. 2009..Mature results are presented from a phase II trial of postoperative concurrent chemoradiotherapy in patients with poor-prognosis cancer of the esophagus and gastroesophageal junction after primary surgical resection... - Human papillomavirus: changing paradigms in oropharyngeal cancerDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Desk R 35, 9500 Euclid Avenue, Cleveland, OH, 44195, USA
Curr Oncol Rep 12:115-20. 2010..The potential for disease prevention with the use of the current HPV vaccines is discussed... - Systemic chemotherapy for squamous cell head and neck cancerDavid J Adelstein
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Desk R 35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Expert Opin Pharmacother 4:2151-63. 2003..In this article, the available data supporting the use of systemic chemotherapy as palliative treatment, and as part of the definitive management for this disease will be reviewed... - An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancerDavid J Adelstein
Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Ohio 44195, USA
J Clin Oncol 21:92-8. 2003..The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer... - Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapyDavid J Adelstein
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 20:1405-10. 2002..Results are reported from an aggressive chemoradiotherapy protocol for advanced squamous cell head and neck cancer... - The role of chemotherapy for skull base carcinomas and sarcomasD J Adelstein
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
Neurosurg Clin N Am 11:681-91. 2000..The ultimate role of this intervention in the aggressive sinonasal undifferentiated carcinomas and primary neuroendocrine carcinomas is unknown, but for these diseases, chemotherapy is a reasonable addition to locoregional treatment... 
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II triaDavid J Adelstein
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Head Neck 32:221-8. 2010....- Oropharyngeal cancer: the role of chemotherapyDavid J Adelstein
The Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Desk R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Curr Treat Options Oncol 4:3-13. 2003..Continued enrollment of patients in well-designed and conducted clinical trials is of paramount importance... - Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapyD J Adelstein
Departments of Hematology and Medical Oncology, Thoracic and Cardiovascular Surgery, Biostatistics and Epidemiology, Radiation Oncology, and Gastroenterology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 18:2032-9. 2000.... - Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancerDavid J Adelstein
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, OH 44195, USA
Lung Cancer 36:167-74. 2002..Patients downstaged to mediastinal node negativity have a prognosis similar to those with de novo stage I(B) and II disease. Distant metastases are the major cause of treatment failure... - A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancerCristina P Rodriguez
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
J Thorac Oncol 5:229-35. 2010..This phase II study added gefitinib (G) to our previously tested CCRT regimen in an effort to improve these outcomes... - Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancerSudish C Murthy
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
J Thorac Oncol 4:395-403. 2009..This study focuses on postesophagectomy benign pleural and pericardial complications to determine their prevalence, temporal pattern, and treatment, and their association with induction chemoradiotherapy and influence on survival... - Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinomaThomas W Rice
Center for Swallowing and Esophageal Disorders and Departmentof Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, OH 44195, USA
J Thorac Cardiovasc Surg 126:1590-6. 2003..We sought to determine whether chemoradiotherapy after esophagectomy improves survival... - Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapyCristina P Rodriguez
Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio, USA
Head Neck 30:1535-42. 2008..Determining which patients benefit from larynx preservation strategies remains problematic. We reviewed our experience using multiagent concurrent chemoradiotherapy to identify clinical predictors for success... - Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancerMalcolm M Decamp
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
J Thorac Cardiovasc Surg 126:17-27. 2003.... - Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapyAnn Tan
Taussig Cancer Center, Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
Arch Otolaryngol Head Neck Surg 133:435-40. 2007.... - Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?Scott A McHam
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk R 35, Cleveland, Ohio 44195, USA
Head Neck 25:791-8. 2003.... - Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neckCristina P Rodriguez
Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
Head Neck 34:1517-23. 2012..This phase II study tested the addition of the oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC)... - Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohortGregory M M Videtic
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
Int J Radiat Oncol Biol Phys 72:702-6. 2008..We used the results of mediastinoscopy from a Stage III NSCLC cohort to assess the reliability of positron emission tomography (PET) scans at identifying involved mediastinal lymph nodes (MLN) when used during radiotherapy planning... - Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinomaThomas W Rice
Center for Swallowing and Esophageal Disorders, Departments of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 125:1091-102. 2003..We sought to evaluate the effectiveness of clinical staging of depth of tumor invasion (cT), the relationship of cT to survival, the benefits of downstaging cT, and the role of cT in treatment decisions... - Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancerRony M Abou-Jawde
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
Chest 128:250-5. 2005..To evaluate the effects of induction concurrent chemoradiotherapy (cCRT) on pulmonary function and postoperative acute respiratory complications (PARCs)... - Refining esophageal cancer stagingThomas W Rice
Center for Swallowing and Esophageal Disorders, Departments of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 125:1103-13. 2003..The objectives of this study were to assess current esophageal cancer staging and to determine whether refinements of classification and stage grouping are necessary... - T2N0M0 esophageal cancerThomas W Rice
Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 133:317-24. 2007..The study objective was to develop a treatment algorithm for cT2N0M0 esophageal cancer by determining (1) errors in clinical staging and (2) consequences of overtreatment and undertreatment of incorrectly clinically staged patients... - Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderlyStephanie A Michal
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Head Neck 34:1147-52. 2012..The reported decreasing benefit with increasing age from concurrent chemoradiotherapy in head and neck cancer patients prompted this retrospective review... - Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classificationGregory M M Videtic
Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
Int J Radiat Oncol Biol Phys 75:1141-7. 2009.... - Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy?Thomas W Rice
The Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA
Ann Thorac Surg 82:2042-9, 2049.e1-2. 2006..Therefore, we determined (1) incidence and prevalence of, risk factors for, and survival after development of brain metastases following esophagectomy for esophageal cancer, and (2) their association with adjuvant therapy... - Endoscopic ultrasound errors in esophageal cancerGregory Zuccaro
Department of Gastroenterology, Cleveland Clinic, Ohio, USA
Am J Gastroenterol 100:601-6. 2005..CONCLUSIONS: EUS errors, particularly in predicting pT, are more frequent than previously reported. Weight loss and tumor length are the only clinical and tumor characteristics correlated with EUS errors... - Factors associated with improved survival in patients with brain metastases from esophageal cancer: a retrospective reviewDeepak Khuntia
Brain Tumor Institute, Department of Radiation Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Technol Cancer Res Treat 2:267-72. 2003..We recommend esophageal cancer patients with BrM be enrolled in clinical trials to better delineate the role of treatment and potentially improve results... - Stage III non-small cell lung cancer and metachronous brain metastasesNader Moazami
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 124:113-22. 2002..This survival benefit is a brain treatment effect, not the result of selecting the best patients for aggressive therapy... - Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical reviewShlomo A Koyfman
Departments of Radiation and Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Int J Radiat Oncol Biol Phys 84:581-9. 2012.... - Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastasesGregory M M Videtic
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Int J Radiat Oncol Biol Phys 67:240-3. 2007..Clinical trials for patients with brain metastases generally exclude small-cell lung cancer (SCLC) cases. We hypothesize that the RPA classes are valid in the setting of SCLC brain metastases... - P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapyP Lavertu
Department of Otolaryngology and Head and Neck Surgery, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
Laryngoscope 111:1878-92. 2001..Closer follow-up may be justified in both p53+ and Ki67+ patients to detect recurrence or a second primary at an earlier stage, possibly improving survival... - Role of positron emission tomography in management of sinonasal neoplasms--a single institution's experienceEric D Lamarre
Head and Neck Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Am J Otolaryngol 33:289-95. 2012..The objective of the study is to examine the utility of positron emission tomography (PET) for staging and restaging after treatment of paranasal sinus carcinomas... - Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiationWalter T Lee
Head and Neck Institute, Cleveland Clinic Foundation, Ohio Desk A71, 9500 Euclid Ave, Cleveland, Ohio 44195, USA
Head Neck 28:808-12. 2006..One side effect is the formation of upper esophageal strictures. As concurrent chemoradiation treatment is used more frequently, it is important to identify risk factors associated with stricture formation... - Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institutionEric D Lamarre
Department of Otolaryngology Head and Neck Surgery, Head and Neck Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Am J Otolaryngol 33:98-103. 2012..Patients were intended to receive single-modality treatment based on presentation; however, some ultimately received adjuvant treatments... - Current developments in the management of locally advanced esophageal cancerMichael J McNamara
Cleveland Clinic Foundation, Taussig Cancer Institute, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
Curr Oncol Rep 14:342-9. 2012..The monoclonal antibody trastuzumab appears to extend survival for patients with metastatic gastric and gastroesophageal junction adenocarcinoma and is under investigation for use in patients with loco-regionally advanced disease... - N1 esophageal carcinoma: the importance of staging and downstagingT W Rice
Department of Thoracic and Cardiovascular Surgery, The Center for Swallowing and Esophageal Disorders, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 121:454-64. 2001..To evaluate the effects of clinical staging and downstaging by induction chemoradiation therapy in patients with N1 esophageal carcinoma... - Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node statusT W Rice
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
Ann Thorac Surg 65:787-92. 1998..A retrospective review of 359 consecutive patients undergoing esophageal resection was conducted to define the relationship between T and N and to determine whether T is a significant predictor of regional lymph node metastasis (N1)... - Is there a role for folate determinations in current clinical practice in the USA?T Latif
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Clin Lab Haematol 26:379-83. 2004..We conclude that determination of serum folate level infrequently led to appropriate folate replacement therapy. Moreover, even when suspected, true folic acid deficiency is rare and clinical indications are not helpful in diagnosis... - Comparison of surgical complications after organ-preservation therapy in patients with stage III or IV squamous cell head and neck cancerP Lavertu
Department of Otolaryngology, Cleveland Clinic Foundation, Ohio 44195, USA
Arch Otolaryngol Head Neck Surg 124:401-6. 1998.... - Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancerT W Rice
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Ohio 44195, USA
Ann Thorac Surg 66:1909-14. 1998..This study assessed toxicity, tumor response, disease control, and survival after short-course induction chemoradiotherapy and surgical resection in patients with stage III non-small-cell lung carcinoma... - Superficial adenocarcinoma of the esophagusT W Rice
Department of Thoracic and Cardiovascular Surgery, The Center for Swallowing and Esophageal Disorders, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Thorac Cardiovasc Surg 122:1077-90. 2001..Experience with treatment and outcome of superficial adenocarcinoma of the esophagus is limited. The purpose of this study was to evaluate the results of surgical management and identify predictors of survival... - Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)Sujith R Kalmadi
Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Lung Cancer 60:259-63. 2008..The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura... - Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube?T M Mekhail
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Cancer 91:1785-90. 2001..Anecdotal observations of prolonged PEG dependence and of a need for pharyngoesophageal dilatation in PEG patients prompted a retrospective review of the use of both types of feeding tubes... - Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinomaG Mercado
University Primary Care Practice, University Hospitals of Cleveland, Cleveland, Ohio, USA
Cancer 92:2892-7. 2001..02). CONCLUSIONS: The authors conclude that the incidence rate of hypothyroidism after patients undergo RT for head and neck carcinoma is higher than generally reported and that TSH screening after treatment appears justified... - Induction redux: once more with taxanesDavid J Adelstein
J Clin Oncol 23:8556-8. 2005 - American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancerDavid G Pfister
American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
J Clin Oncol 24:3693-704. 2006.... - Redefining the role of induction chemotherapy in head and neck cancerDavid J Adelstein
J Clin Oncol 26:3117-9. 2008 - Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group TrialSusan G Urba
University of Michigan Medical Center, Ann Arbor, USA
J Clin Oncol 23:88-95. 2005..CONCLUSION: Patients with base of tongue or hypopharyngeal cancer treated with this regimen of induction chemotherapy followed by definitive chemoradiotherapy have a good rate of organ preservation without compromise of survival...